India, March 27 -- The Government of India has issued a release:
Cumulative investment (in crore Rs.) till
Employment (Nos.) opportunities generated till
March 2023
March 2024
March 2025
December 2025
March 2023
March 2024
March 2025
December 2025
PLI Scheme for Bulk Drugs
2,374.93
3,721.44
4,554.25
4,814.10
2,163
3,538
4,490
4,896
PLI Scheme for Pharmaceuticals
20,647
29,268
37,306.65
42,694.89
46,357
70,362
93,532
1,13,300
S. No.
Name of Products covered under PLI Scheme for Bulk Drugs
Penicillin G
7-ACA
Clavulanic Acid
Erythromycin Thiocyanate (TIOC)
Betamethasone
Dexamethasone
Prednisolone
Rifampicin
Clindamycin Base
Streptomycin
Tetracycline
Neomycin
Gentamycin
Para Amino Phenol
1,1 Cyclohexane Diacetic Acid (CDA)
Dicyandiamide (DCDA)
2-Methyl-5-Nitro-Imidazole (2-MNI)
Meropenem
Atorvastatin
Olmesartan
Valsartan
Losartan
Levofloxacin
Sulfadiazine
Ofloxacin
Norfloxacin
Artesunate
Telmisartan
Aspirin
Levetiracetam
Carbidopa
Ritonavir
Lopinavir
Acyclovir
Carbamazepine
Oxcarbazepine
Vitamin B6
Levodopa
Vitamin B1
Diclofenac Sodium
Ciprofloxacin
The status of implementation of Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs) / Drug Intermediates (DIs) and Active Pharmaceutical Ingredients (APIs) in India (commonly known as "PLI scheme for Bulk Drugs") is as follows:
i. Till December 2025, investment of Rs.4,814 crore has been made against an investment commitment of Rs.4,329.95 crore in greenfield projects.
ii. Total capacity amounting to 91,077 metric tonnes per annum is committed for 33 subscribed products as against originally envisaged capacity of 82,270 metric tonnes per annum for 41 products identified (List of 41 products is placed at Annexure). Further, manufacturing capacity of 56,800 metric tonnes per annum has been created for 28 critical KSMs, DIs, and APIs till December, 2025. The scheme has resulted in cumulative sales of Rs.2,720 crore, including exports of Rs.527.96 crores.
Department of Pharmaceuticals is implementing a scheme, namely the scheme for Promotion of Bulk Drug Parks, with a budgetary outlay of Rs.3,000 crore, under which three bulk drug parks have been approved and are at various stages of development in the States of Andhra Pradesh, Gujarat and Himachal Pradesh, through their respective State implementing agencies. The total project cost of these parks is over Rs.6,306.68 crore, with Central assistance to the tune of Rs.1,000 crore each for creation of common infrastructure facilities. These parks envisage land and utilities such as power, water, effluent treatment plant, steam, solid waste management and warehouse facilities at a subsidised rate to bulk drug or API manufacturers for units set up in the park. The State implementing agencies of the States concerned have also offered fiscal incentives in the form of capital subsidy on fixed capital investment, interest subsidy, State Goods and Services Tax reimbursement, exemption of stamp duty and registration charges, etc. Further, the scheme provides for applicants for allotment of land in the parks to set up units for manufacturing products prioritised in the PLI Scheme for Bulk Drugs to have priority in land allotment.
The Production Linked Incentive (PLI) scheme aims to enhance India's manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc.
The total cumulative investment attracted and the number of direct and indirect employment opportunities generated in the pharmaceutical sector since the launch of the said schemes, year- wise is given below:
Annexure
This information was given by Minister of State for Chemicals and Fertilizers, Smt. Anupriya Patel, in a written reply in the Lok Sabha today.
Disclaimer: Curated by HT Syndication.
